These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1138 related items for PubMed ID: 28058658

  • 21. MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy.
    Tran KA, Cheng MY, Mitra A, Ogawa H, Shi VY, Olney LP, Kloxin AM, Maverakis E.
    Drug Des Devel Ther; 2016; 10():43-52. PubMed ID: 26730180
    [Abstract] [Full Text] [Related]

  • 22. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
    Gogas HJ, Flaherty KT, Dummer R, Ascierto PA, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Sileni VC, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Gollerkeri A, Pickard MD, Robert C.
    Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754
    [Abstract] [Full Text] [Related]

  • 23. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
    Fauviaux E, Promelle V, Boucenna V, Jany B, Errera MH, Delbarre M, Boucenna W.
    J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
    [Abstract] [Full Text] [Related]

  • 24. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
    Galliker NA, Murer C, Kamarashev J, Dummer R, Goldinger SM.
    Eur J Dermatol; 2015 Apr; 25(2):177-80. PubMed ID: 25788221
    [Abstract] [Full Text] [Related]

  • 25. Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.
    Zia Y, Chen L, Daud A.
    Expert Opin Pharmacother; 2015 Apr; 16(14):2257-63. PubMed ID: 26331795
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
    Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S.
    J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
    [Abstract] [Full Text] [Related]

  • 29. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
    Sullivan RJ, Hamid O, Gonzalez R, Infante JR, Patel MR, Hodi FS, Lewis KD, Tawbi HA, Hernandez G, Wongchenko MJ, Chang Y, Roberts L, Ballinger M, Yan Y, Cha E, Hwu P.
    Nat Med; 2019 Jun; 25(6):929-935. PubMed ID: 31171876
    [Abstract] [Full Text] [Related]

  • 30. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
    Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L, Gilmer TM.
    Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
    [Abstract] [Full Text] [Related]

  • 31. Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors.
    Wahid M, Jawed A, Mandal RK, Dar SA, Akhter N, Somvanshi P, Khan F, Lohani M, Areeshi MY, Haque S.
    Crit Rev Oncol Hematol; 2018 May; 125():84-88. PubMed ID: 29650281
    [Abstract] [Full Text] [Related]

  • 32. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
    Fattore L, Malpicci D, Marra E, Belleudi F, Noto A, De Vitis C, Pisanu ME, Coluccia P, Camerlingo R, Roscilli G, Ribas A, Di Napoli A, Torrisi MR, Aurisicchio L, Ascierto PA, Mancini R, Ciliberto G.
    Oncotarget; 2015 Sep 22; 6(28):24823-41. PubMed ID: 26208478
    [Abstract] [Full Text] [Related]

  • 33. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
    Martin-Liberal J, Larkin J.
    Future Oncol; 2015 Sep 22; 11(4):579-89. PubMed ID: 25686114
    [Abstract] [Full Text] [Related]

  • 34. Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.
    Schmitt AM, Dumas L, Larkin J.
    Expert Rev Anticancer Ther; 2022 Jan 22; 22(1):17-25. PubMed ID: 34904502
    [Abstract] [Full Text] [Related]

  • 35. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
    Martin CA, Cullinane C, Kirby L, Abuhammad S, Lelliott EJ, Waldeck K, Young RJ, Brajanovski N, Cameron DP, Walker R, Sanij E, Poortinga G, Hannan RD, Pearson RB, Hicks RJ, McArthur GA, Sheppard KE.
    Int J Cancer; 2018 May 15; 142(10):2139-2152. PubMed ID: 29243224
    [Abstract] [Full Text] [Related]

  • 36. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, Galvin K, Okaniwa M, Ishikawa T, Yoshida S.
    Cancer Res; 2013 Dec 01; 73(23):7043-55. PubMed ID: 24121489
    [Abstract] [Full Text] [Related]

  • 37. A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.
    Russo I, Zorzetto L, Frigo AC, Chiarion Sileni V, Alaibac M.
    Eur J Dermatol; 2017 Oct 01; 27(5):482-486. PubMed ID: 29084636
    [Abstract] [Full Text] [Related]

  • 38. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
    Sloot S, Zager JS, Kudchadkar RR, Messina JL, Benedict JJ, Gonzalez RJ, DeConti R, Turner LM, McCardle T, Smalley KS, Weber JS, Sondak VK, Gibney GT.
    Melanoma Res; 2016 Feb 01; 26(1):83-7. PubMed ID: 26731560
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 57.